Inflammatory Bowel Diseases (IBD)

Latest News

Clinical Tool Helps Optimize Vedolizumab Treatment in Patients With Ulcerative Colitis

By

Colby Stong

An international team of investigators created a clinical decision support tool to assist in identifying patients with ulcerative colitis most likely to benefit from treatment with vedolizumab.

De-Escalation and Discontinuation of Biologics in IBD: What to Consider

By

C. Andrew Kistler, MD, PharmD

Although the definition of remission varies, the goal of IBD treatment is to achieve and sustain remission.

Bacterial and Fungal Profiles Estimate Infliximab Response in Patients With IBD

By

Virginia A. Schad, PharmD, RPh

A team of investigators sought to determine the influence of infliximab on gut bacterial and fungal composition in patients with inflammatory bowel disease.

The Crohn’s Anal Fistula Quality of Life Scale: A Patient-Reported Outcome Measure

By

Virginia A. Schad, PharmD, RPh

As Crohn disease perianal fistulas often do not respond to available treatments, researchers developed a patient-derived quality-of-life tool to evaluate the impact of the condition on patients.

Increased Proteolytic Activity in Feces May Be Potential Biomarker of Ulcerative Colitis

By

Jessica Nye, PhD

A team of investigators studied a group of asymptomatic patients who were at increased risk of developing inflammatory bowel disease to assess proteolytic activity in advance of a diagnosis of ulcerative colitis.

Study Finds Similar Outcomes in Patients With, Without IBD and Rectal Cancer

By

Vincent Soreca

A team of researchers from the Mayo Clinic aimed to assess survival among patients with rectal cancer with or without inflammatory bowel disease.

Chronic Immune-Mediated Diarrhea and Colitis Associated With Prolonged Survival in Patients Treated With ICIs

By

Susan Moench, PhD, PA-C

The immune-related AE, immune-mediated diarrhea and colitis, can have a limited course or may exist for long-term periods.

Clinical Remission Observed With Risankizumab in Crohn Disease Trials

By

Brian Park, PharmD

Risankizumab is currently FDA-approved under the brand name Skyrizi for the treatment of moderate to severe plaque psoriasis.

Improved Psychological Support Is Needed After Stoma Surgery

By

Jessica Nye, PhD

Interview study identified categories in which improved psychological support services are needed for these patients.

Socioeconomic Status Influences Inflammatory Bowel Disease Outcomes

Lower socioeconomic status is associated with worse outcomes for inflammatory bowel disease.

Genetic Risk May Predict Thromboembolic Disease in Inflammatory Bowel Disease

By

Emily Pond

Thromboembolic disease risk in people with inflammatory bowel disease may be influenced by patient genetics, including polygenic risk scores.

CONUT Score Effectively Stratifies Risk for Postoperative Complications in Crohn Disease

By

Jessica Nye, PhD

Investigators assessed the Controlling Nutritional Status’ (CONUT’s) efficacy in predicting postoperative complications in patients with Crohn disease.

Expanded Insight Guides Therapeutic Strategy in IBD Amid COVID-19

By

Rachel Narozniak, MA

Although the emergence of COVID-19 initially called the continuation of inflammatory bowel disease (IBD) therapy into question, treatment has proceeded — albeit with added considerations.

A History of Depression and Gastrointestinal Symptoms May Predict Risk for Subsequent IBD

By

Jessica Nye, PhD

Investigators assessed whether depression, adjusted for preexisting gastrointestinal symptoms, is associated with subsequent inflammatory bowel disease.

Treatment for Acute Severe Ulcerative Colitis in Pregnant Women Is Safe and Effective

By

Colby Stong

Investigators studied the outcomes of pregnant women hospitalized with acute severe ulcerative colitis.

Study Identifies Novel Plasma Proteomic Biomarkers for Crohn Disease Complications

By

Virginia A. Schad, PharmD, RPh

Investigators used a machine learning strategy to seek out plasma protein biomarkers for stricturing and penetrating complications.

Helmsley Trust Awards Grants to Three Studies Developed to Inform Evidence-Based Dietary Recommendations in Crohn Disease

By

Rachel Narozniak, MA

The Leona M. and Harry B. Helmsley Charitable Trust awarded grants to 3 studies, the results from which will inform evidence-based recommendations for dietary intervention in Crohn disease.

Extended Tofacitinib Induction Therapy Safely Elicits Clinical Responses in Ulcerative Colitis

By

Jessica Nye, PhD

Investigators tested the safety and efficacy of an additional 8-week course of tofacitinib monotherapy in patients with ulcerative colitis to determine whether a longer course of induction therapy would induce clinical responses.

Genetic Variants in IBD Associated With Heightened Risk for Thromboembolic Disease

Genetic variants in some patients with inflammatory bowel disease were found to be associated with a significantly increased risk for developing thromboembolic disease.

Marked Decline in 5-Year Surgery Rates Seen for Ulcerative Colitis, Crohn Disease

By

Emily Pond

Investigators analyzed the surgical risk for ulcerative colitis and Crohn disease in contemporary, population-based inception cohorts vs 20th century cohorts.